ACADIA Pharmaceuticals Inc.
Price Action
Technical Summary
EMERGING TRENDACADIA Pharmaceuticals Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 82% provides fundamental context to the price action. However, with RSI at 75, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $23.17 | +13.07% | ABOVE |
| 50 SMA | $22.29 | +17.54% | ABOVE |
| 100 SMA | $22.27 | +17.64% | ABOVE |
| 150 SMA | $23.61 | +10.98% | ABOVE |
| 200 SMA | $23.29 | +12.50% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ACAD in an uptrend right now?
ACAD has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ACAD overbought or oversold?
ACAD's RSI (14) is 75. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ACAD outperforming the market?
ACAD has a Relative Strength (RS) Rating of 65 out of 99. ACAD is performing about average compared to the market.
Where is ACAD in its 52-week range?
ACAD is trading at $26.20, which is 94% of its 52-week high ($27.81) and 80% above its 52-week low ($19.69).
How volatile is ACAD?
ACAD has a Beta of 1.00 and 52-week volatility of 38%. It's more volatile than the S&P 500 - expect bigger swings.